How much funding has Indalo Therapeutics raised?

Indalo Therapeutics has raised $26.0M in total funding, most recently a Series A round.

When was Indalo Therapeutics founded?

Indalo Therapeutics was founded in 2016.

Where is Indalo Therapeutics headquartered?

Indalo Therapeutics is headquartered in St. Louis, Missouri, United States.

What industry is Indalo Therapeutics in?

Indalo Therapeutics operates in Biotech, Healthcare.

Indalo Therapeutics

Q: Who are Indalo Therapeutics's investors?

Indalo Therapeutics's investors include Atlas Venture, F-Prime Capital, Missouri Technology Co.

St. Louis, United States · Founded 2016 · $26.0M raised

Biotech

Healthcare

Headquarters: St. Louis, Missouri
Founded: 2016
Business Model: B2B

Total Funding: $26.0M
Last Round: $26.0M Series AAug 2017
Rounds: 1

About

Indalo Therapeutics is a St. Louis-based biopharmaceutical company formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. The company discovers and develops integrin antagonist therapies, including lead candidate IDL-2965, to treat serious fibrotic diseases such as idiopathic pulmonary fibrosis and NASH. Indalo has advanced its programs through Phase 1 clinical trials, backed by an experienced management team, strong intellectual property, and investors including Atlas Venture and F-Prime Capital.

Summary

Indalo Therapeutics is a Biotech company based in St. Louis, United States, founded in 2016. It has raised $26.0M in total across 1 round, most recently a $26.0M Series A round in Aug 2017. Investors include Atlas Venture, F-Prime Capital and Missouri Technology Co.